Recce Pharmaceuticals (ASX:RCE) has secured human research ethics committee approval to allow up to 20 additional patients in its phase two clinical study to access Recce 327, a topical gel designed for diabetic foot infections (DFI), according to a Tuesday filing with the Australian bourse.
The study will run concurrently with Recce's phase three trial in Indonesia, which is expected to deliver results later in the year, with regulatory approval and commercial launch anticipated in the first half of 2026, the filing said.
Both studies aim to generate additional data to support future regulatory submissions, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。